|
Ms. Swearson brings to Receptor BioLogix an extensive background in successful financial management, fund raising, team building and mergers and spin-outs of early-stage life science companies. Prior to joining the company, she served as CFO, vice president, finance and operations at Threshold Pharmaceuticals, Inc., where she was instrumental in raising $151 million in public and private funds (including an IPO and a follow-on financing). Previously, she was CFO, vice president, finance and administration at Camitro Corp. until its sale to a public company. She has also served in a variety of finance and operations positions at IntraBiotics Pharmaceuticals, Inc., at Affymax participating in its IPO, sale to Glaxo Wellcome and the spin-outs of Affymetrix and Maxygen, and at Monoclonal Antibodies, Inc., until its merger with Quidel Corp. Prior to biotechnology, Ms. Swearson worked at Hewlett Packard. She received her B.A. at the University of Minnesota and her M.B.A. at Santa Clara University. | 